Ipsen's Iqirvo® ( elafibranor ) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
PARIS, FRANCE, 20 September 2024 - Ipsen ( Euronext: IPN. ADR: IPSEY ) announced today that the European Commission has conditionally approved Iqirvo® ( elafibranor ) 80mg tablets for the treatment of primary biliary cholangitis ( PBC ) in combination with ursodeoxycholic acid ( UDCA ) in adults ...
| Ticker |
Sentiment |
Impact |
|
GNFT
|
Neutral
|
4 %
|
|
CURN
|
Neutral
|
2 %
|
